Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report

BACKGROUND: Denosumab and abiraterone were approved by the United States Food and Drug Administration in 2011 for the treatment of metastatic castration-resistant prostate cancer. Neither denosumab nor abiraterone is known to cause rhabdomyolysis. CASE PRESENTATION: A 76-year-old Caucasian man with...

Descripción completa

Detalles Bibliográficos
Autores principales: Neyra, Javier A., Rocha, Natalia A., Bhargava, Rhea, Vaidya, Omkar U., Hendricks, Allen R., Rodan, Aylin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519001/
https://www.ncbi.nlm.nih.gov/pubmed/26220655
http://dx.doi.org/10.1186/s12882-015-0113-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519001/
https://www.ncbi.nlm.nih.gov/pubmed/26220655
http://dx.doi.org/10.1186/s12882-015-0113-6

Ejemplares similares